Nexplanon (etonogestrel implant) / Organon - LARVOL DELTA

CONTRACEPTION PREFERENCES OF WOMEN AND HEALTHCARE PROVIDERS: A DISCRETE CHOICE EXPERIMENT (ISPOR 2026) - "When considering long-acting reversible methods, women had a slight preference for the etonogestrel implant compared to intrauterine devices... Women and HCPs strongly prefer highly effective contraception. These findings, showing similarities and differences in stated preferences between women and HCPs, are central to informing educational efforts, contraceptive counseling, benefit-risk, and resource allocation."

Clinical • Cardiovascular • Gynecology • Long-acting Reversible Contraceptives • Obstetrics • Women's Health

WILLINGNESS TO TRADE EFFECTIVENESS FOR OTHER CONTRACEPTIVE FEATURES: A DISCRETE CHOICE EXPERIMENT (ISPOR 2026) - "Notable tradeoffs are willing to be made when considering various contraceptive attributes. These findings are central to educational efforts, contraceptive counseling, benefit-risk, and resource allocation."

Cardiovascular • Gynecology • Long-acting Reversible Contraceptives • Obstetrics • Women's Health

Contraception in women at increased thromboembolic risk (ISGE 2026) - "Combined oral contraceptives (COCs) increase the risk of VTE compared with non-use, with the lowest rate in ethinylestradiol + levonorgestrel or norgestimate or natural estradiol/estetrol formulations. In conclusion, contraceptive choice in women at elevated thrombo-embolic risk should emphasize non-estrogenic methods, individualized assessment, and continuous revaluation. Long-acting reversible contraception, especially copper or LNG-IUSs and etonogestrel implants, provides optimal safety and efficacy, aligning with current recommendations to minimize estrogen-related thrombosis."

Clinical • Cardiovascular • CNS Disorders • Genetic Disorders • Hematological Disorders • Hypertension • Long-acting Reversible Contraceptives • Migraine • Obesity • Venous Thromboembolism

Satisfaction and continuation rates with LARCs in a Public Family Planning Service in Brazil (ISGE 2026) - "Until recently, the only LARC available was the copper intrauterine device (Cu-IUD), while the etonogestrel implant was restricted to women in vulnerable conditions... Implant users showed significantly higher continuation rates than Cu-IUD users. Despite high satisfaction, adverse symptoms—especially dysmenorrhea and increased bleeding—were more frequent with Cu-IUDs. Strengthening pre-insertion counseling may align expectations, reduce discontinuation, and improve adherence to LARCs."

Long-acting Reversible Contraceptives • Women's Health

Satisfaction rate among women with congenital heart disease using a 68 mg etonogestrel-releasing subdermal implant: a cross-sectional study (ISGE 2026) - "Women with congenital heart disease using the 68 mg etonogestrel-releasing subdermal implant showed a high satisfaction rate, indicating good acceptance and adherence to the method. These findings support the 68 mg etonogestrel implant as an effective, safe, and well-accepted contraceptive option for women with congenital heart disease, contributing to the prevention of high-risk pregnancies and the promotion of reproductive health in this population."

Clinical • Observational data • Cardiovascular • Gynecology • Heart Failure • Women's Health

Single centre experience of Implanon-Nxt, the newly introduced single rod subdermal contraceptive implant in India (ISGE 2026) - "Implanon-Nxt, an etonogestrel containing subdermal implant has expanded the choices for long-acting reversible contraceptives (LARC). In the initial three years of implant use as a contraceptive, there was high continuation rate of 91.69%. The most common reason for premature removal was heavy bleeding or continuous spotting."

Clinical • Long-acting Reversible Contraceptives • Pruritus

Acceptance of contraceptive methods after obstetric outcome in a public healthcare service. (ISGE 2026) - "For those that opted for LARCs, 57.4% (n=241) chose for etonogestrel implant, 22.1% ( n=93) for Levonorgestrel-SIU and 10.2% (n=43) for Cu-IUD... LARCs are chosen for the most women after an obstetric outcome if contraceptives are offered by demand when the cost and lack of information are eliminated. More studies are necessary to analyze the continued use of LARCs after an obstetric outcome and the reduction of unintended pregnancy in that population."

Long-acting Reversible Contraceptives • Obstetrics

In brief: Extended duration of use for Nexplanon. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal

Traumatic In-Situ Fracture of an Etonogestrel Implant (Nexplanon®) Presenting as Altered Palpation Without Bleeding: A Case Report and Review of Literature. (PubMed, Cureus) - "She declined immediate replacement. Traumatic implant fracture may present solely as altered palpation. Clinicians should assess integrity after arm trauma, use imaging if nonpalpable, confirm complete removal, and offer immediate replacement of contraception."

Journal • Anesthesia • Musculoskeletal Diseases • Orthopedics

Subdermal contraceptive implant migration to the pulmonary vasculature: A case report. (PubMed, Case Rep Womens Health) - "This report concerns the case of a 22-year-old woman who presented for removal of a non-palpable etonogestrel implant...Pulmonary migration of contraceptive implants is rare but potentially serious. Delayed diagnosis may preclude endovascular removal."

Journal • Cardiovascular • Long-acting Reversible Contraceptives • Pulmonary Embolism

Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON (etonogestrel implant) 68 mg Radiopaque (FinancialContent) - "The sNDA extends the duration of use of NEXPLANON for up to five years, an extension of the previous three-year indication. During the clinical trial to assess the contraceptive efficacy and safety of extended use (years 4 and 5), no pregnancies were reported and there were no new safety findings."

FDA approval • Women's Health

Treatment of unfavorable bleeding patterns in contraceptive implant users with tranexamic acid: randomized clinical trial. (PubMed, Am J Obstet Gynecol) - "A 5-day treatment course of TXA did not improve bleeding in contraceptive ENG-implant users experiencing frequent or prolonged bleeding patterns."

Clinical • Journal • Long-acting Reversible Contraceptives • Obstetrics

Clinical evaluation of a low-cost and high-fidelity animal model for palpable and nonpalpable implant removal. (PubMed, Contraception) - "Our chicken leg model could be relevant, effective and useful as a training program for healthcare professionals involved in deep implant removal."

Journal • Preclinical • Long-acting Reversible Contraceptives

A five-year cost-consequence analysis of extended-use etonogestrel implant versus other contraceptives. (PubMed, J Med Econ) - "A discrete Markov chain model with 5-year time horizon simulated pregnancy outcomes among 1,000 women 18-49 years initiating 1 of 8 hormonal contraceptive branded or generic oral contraception (OC; progestin only and combined), medroxyprogesterone acetate injection, etonogestrel/ethinyl estradiol vaginal ring, norelgestromin/ethinyl estradiol transdermal patch, 3- or ≥5-year levonorgestrel IUD, and the etonogestrel implant. The etonogestrel implant was the most cost-effective contraceptive option when modeled over a 5-year period, offering the fewest pregnancies and lowest associated healthcare costs. Policies and practices that support initiation and continuation of the etonogestrel implant can enhance both clinical outcomes and overall cost-effectiveness."

Journal • Long-acting Reversible Contraceptives

Is the Availability of Immediate Inpatient Postpartum Long-Acting Reversible Contraception (LARC) Associated with a Decrease in Rapid Repeat Pregnancy? (PubMed, J Am Board Fam Med) - "After SB 332's passage, IPP-LARC availability was positively associated with RRP, but the percentage of patients who chose IPP-LARC was low. However, RRP occurred less often among patients who chose IPP-LARC placement. Hospital systems must actively invest in patient education and provider support to ensure interventions to reduce rapid repeat pregnancy are optimally utilized by vulnerable populations."

Journal • Long-acting Reversible Contraceptives • Obstetrics • Preventive care • Small for Gestational Age • Women's Health

Hormonal long-acting reversible contraceptives use and potential impact on environment: A mathematical model. (PubMed, Int J Gynaecol Obstet) - "Use of hormonal LARCs is associated with a substantially lower annual environmental waste footprint impact compared with COCs and nonuse of contraception, owing to reduced solid waste generation and fewer disposable menstrual hygiene products used."

Journal • Long-acting Reversible Contraceptives

Immediate postpartum etonogestrel implant placement and breastfeeding-can we safely abandon the 24-hour rule? (Letter-to-the-Editor). (PubMed, Am J Obstet Gynecol) - No abstract available

Journal

Pulmonary embolism of subdermal contraceptive implant: lung-sparing precision removal. (PubMed, BMJ Case Rep) - "We report the case of a woman in her late 20s with a non-palpable Nexplanon implant, found within a segmental branch of the right lower lobe pulmonary artery...This case highlights a precision surgical approach to remove a pulmonary artery-embedded contraceptive implant without sacrificing lung parenchyma. It underscores the importance of shared decision-making and a tailored, multidisciplinary approach in managing rare device-related complications."

Journal • Cardiovascular • Long-acting Reversible Contraceptives • Pain • Pulmonary Embolism • Respiratory Diseases

Effectiveness of the etonogestrel implant: an economic model of immediate postpartum use on pregnancy outcomes. (PubMed, J Med Econ) - "A Markov model with 1-year time horizon simulated pregnancy outcomes among 1,000 women 18-49 years initiating 1 of 8 hormonal contraceptives for postpartum contraception: progestin-only oral contraception (OC), combined OC, progestin-only injectable, etonogestrel/ethinyl estradiol vaginal ring, norelgestromin/ethinyl estradiol transdermal patch, 3- or ≥5-year levonorgestrel IUD, and the etonogestrel implant. The immediate postpartum provision of the etonogestrel implant produced the greatest cost savings due to fewer short-interval pregnancies and related expenditures. These results highlight the etonogestrel implant as a cost-effective option for clinicians seeking to reduce short-interval pregnancy and health system costs."

Journal • Long-acting Reversible Contraceptives

FEATS: Failed Endometrial Ablation Treatment With Implantable Progesterone (FEAT) Study (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Saskatchewan Health Authority - Regina Area | Terminated ➔ Withdrawn

Trial withdrawal • Women's Health

Survey of Birth Control Practices in People with Epilepsy of Child-bearing Potential (PWECP) – Single Center Data (AES 2025) - "9/102 (8.8%) participants reported using contraception to prevent seizures.The most common antiseizure medications used were levetiracetam, 54/102 (52.9%), and lamotrigine 35/102 (34.3%) (Table 2). These results suggest that there are gaps in contraception counseling and awareness among PWECP. OCPs are the most commonly used contraceptive in PWECP as well as the NSFG. Use of depot medroxyprogesterone acetate and etonogestrel implants was higher in our sample than in the NSFG.This project will be expanded to multiple sites across the United States to obtain large-scale data."

Clinical • CNS Disorders • Epilepsy • Long-acting Reversible Contraceptives

Deep implant removal: The impact of implant depth and positioning. (PubMed, Int J Gynaecol Obstet) - "Difficult implant removals, including surgical extractions, are strongly associated with inadequate placement and fibrosis. These factors significantly increase the complexity of removal, emphasizing the need for proper insertion training and early identification of high-risk cases to reduce surgical interventions."

Journal • Fibrosis • Immunology • Long-acting Reversible Contraceptives

Depression, Anxiety, and Stress in Adolescents Using the Etonogestrel Implant: A Prospective Cohort Study. (PubMed, J Pediatr Adolesc Gynecol) - "Use of the etonogestrel implant was not associated with significant changes in depression, anxiety, or stress symptoms among adolescents over six months. The findings support the psychological safety of the method and suggest that mood symptoms are more common in this population and are more likely related to developmental factors than to contraceptive use."

Journal • CNS Disorders • Depression • Long-acting Reversible Contraceptives • Mood Disorders • Psychiatry

Subdermally Placed Implanon Migration Into the Pectoralis Muscle and Its Removal in a Resource-Limited Setup: A Case Report and Brief Literature Review. (PubMed, Clin Case Rep) - "Due to their effectiveness, convenience, and reversibility, single-rod etonogestrel devices such as Implanon and Nexplanon are increasingly popular as long-acting reversible contraceptive methods...Ultimately, ultrasound-guided removal was successfully performed by a multidisciplinary team. This case highlights the importance of image-guided techniques for safe and effective implant retrieval, rather than relying on blind surgical exploration."

Journal • Long-acting Reversible Contraceptives

SDRIFE due to Nexplanon®: A Rare Reaction to a Widely Used Contraceptive (ACAAI 2025) - "Commonly implicated drugs include beta-lactam antibiotics, especially amoxicillin, but other antibiotics such as clindamycin, metronidazole, and fluconazole have also been reported. The temporal relationship and resolution following removal suggest a strong causal link. Clinicians should consider hormonal implants in the differential diagnosis of symmetric intertriginous rashes, particularly in patients recently exposed to systemic medications or devices."

Dermatitis • Gastrointestinal Disorder • Immunology • Long-acting Reversible Contraceptives